AbbVie Receives FDA Approval for Emrelis in c-Met Overexpressing Non-Small Cell Lung Cancer

AbbVie today announced that the FDA has granted accelerated approval to Emrelis (telisotuzumab vedotin-egdr) for adults with previously treated c-Met overexpressing non-squamous non-small cell lung cancer (NSCLC). Emrelis is a c-Met-directed antibody-drug conjugate (ADC) that delivers a microtubule-disrupting payload to c-Met-expressing cancer cells. In the LUMINOSITY trial, Emrelis demonstrated an overall response rate of 35% in patients with c-Met high overexpression. The median duration of response was 7.2 months. This approval provides a new targeted treatment option for patients with c-Met overexpressing NSCLC.